Aclarion, Inc. (ACONW)
| Market Cap | 7.90M +99.9% |
| Revenue (ttm) | 77,879 +42.6% |
| Net Income | -8.05M |
| EPS | -7.97 |
| Shares Out | 2.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 468 |
| Open | 0.0313 |
| Previous Close | 0.0315 |
| Day's Range | 0.0313 - 0.0313 |
| 52-Week Range | 0.0214 - 0.2333 |
| Beta | 1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About ACONW
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standa... [Read more]
News
Aclarion Quarterly report: Q1 2026
Aclarion has published its Q1 2026 quarterly earnings report on May 13, 2026.
Aclarion enters second commercial agreement with Weill Cornell Medicine
Aclarion (ACON) announced it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/We...
Aclarion Proxy statement: Proxy filing
Aclarion filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Aclarion announces $2.5M share repurchase program
Aclarion (ACON) announced that its board of directors has authorized a share repurchase program of up to $2.5M of the company’s outstanding common stock. Aclarion expects to execute the repurchase…
Aclarion granted U.S. patent for AI-driven back pain assessment
Aclarion (ACON) announced the issuance of a U.S. patent covering its machine learning-based platform for analyzing magnetic resonance spectroscopy, or MRS, data. Aclarion’s cloud-based platform, Nocis...
Aclarion Receives Pinnacle Award for AI Innovation
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion,...
Aclarion announces commercial agreement with Weill Cornell Medicine
Aclarion (ACON) announced it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cor...
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The Londo...
Aclarion Proxy statement: Proxy filing
Aclarion filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Echo Lake calls on Aclarion director David Neal to resign
Ephraim Fields of Echo Lake Capital sent a letter to David Neal, a member of the Board of Directors of Aclarion (ACON). The letter read, in part, “We believe we…
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.
Stock has declined 99% since its IPO Believes Neal has repeatedly failed to fulfill his fiduciary responsibility Since 2021 Neal has received $240,000 Board compensation Accepted 20% pay increase in 2...
Aclarion adopts limited duration stockholder rights plan
Aclarion (ACON) announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan. The Rights Plan is effective immediately and expires in one year. The Rights…
Aclarion’s CEO publishes shareholder letter
Aclarion (ACON)published a shareholder letter from CEO Brent Ness providing an update on the company’s recent momentum and value-creating priorities for 2026. The letter highlights Aclarion’s “continu...
Aclarion Annual report: Q4 2025
Aclarion has published its Q4 2025 annual report on March 18, 2026.
Aclarion strengthens balance sheet, extends cash runway into 2028
Aclarion (ACON) announced the closing of a $10.4M common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially strengthens Aclarion’s balance sheet, pr...
Aclarion Inc trading halted, volatility trading pause
09:59 EST Aclarion (ACON) Inc trading halted, volatility trading pause
Why Is Aclarion Stock (ACON) Up Today?
Aclarion stock gained on Thursday alongside a corporate update and new guidance.
Aclarion says first patients enrolled at two additional CLARITY trial sites
Aclarion (ACON) announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the company’s pivotal CLARITY trial, advancing enrollment progress in the trial. The compa...
Aclarion announces publication of Nociscan article in pain issue of IJSS
Aclarion (ACON) announced the publication of a featured article Tech Update, sponsored by Aclarion, in the upcoming Special Pain Issue of the International Journal of Spine Surgery, IJSS. “We are…
Aclarion appoints Jason Brosniak as commercial director, Eastern U.S.
Aclarion (ACON) announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S. Jason is a proven commercial leader with more than 20 years of experience accelerating revenue growth a...
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technol...
Aclarion Quarterly report: Q3 2025
Aclarion has published its Q3 2025 quarterly earnings report on November 12, 2025.
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion's breakthrough Nociscan solution for chronic low back pain ...
Aclarion Transcript: LD Micro Main Event XIX Investor Conference
Strong financial footing and NASDAQ compliance support rapid growth in a $10B+ market, driven by a patented, AI-powered SaaS diagnostic for chronic back pain. Clinical trials and payer adoption in London and the U.S. are accelerating physician uptake and scan volumes.